Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD1 | Q15139 | 4/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311194 | 0.89 | MAPT (0.37) | PRKD1PRKD3PRKD2MAPTGLA | |
| SCHEMBL6311645 | 0.87 | MAPT (0.40) | PRKD1PRKD3PRKD2MAPTGLA | |
| SCHEMBL6311672 | 0.86 | PRKD1 (0.36) | PRKD1PRKD3PRKD2MAPTGLA | |
| SCHEMBL6314245 | 0.85 | MAPT (0.39) | PRKD1PRKD3PRKD2MAPTGLA | |
| SCHEMBL6313053 | 0.84 | MAPT (0.40) | PRKD1PRKD3PRKD2MAPTGLA | |
| SCHEMBL6320340 | 0.84 | PIM1 (0.37) | PRKD1PRKD3PRKD2MAPTCDK1 | |
| SCHEMBL6313859 | 0.84 | PER2 (0.38) | PRKD1PRKD3PRKD2MAPTPOLB | |
| SCHEMBL6311862 | 0.83 | MAPT (0.40) | PRKD1PRKD3PRKD2MAPTGLA | |
| SCHEMBL6313536 | 0.82 | KAT2B (0.45) | POLBSMN1; SMN2 | |
| SCHEMBL6311611 | 0.82 | MAPKAPK2 (0.55) | PRKD1MAPTPDE4ATDP1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250765-A1 | Diazepinones as antiviral agents | CHO HIDETSURA | 2005-11-10 | — | — | US | claimed |
| US-20040116410-A1 | Diazepinones as antiviral agents | CHO HIDETSURA (JP) | 2004-06-17 | — | — | US | claimed |
| WO-2002014324-A2 | DIAZEPINONES AS ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250765-A1 | Diazepinones as antiviral agents | ZC3HAV1, ECI1, ZC3HAV1L | PRKD1 3179/4885PRKD3 2993/4885PRKD2 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.